Introduction {#Sec1}
============

New research shows a growing interest towards cryotherapy or regional hypothermia for alleviating chemotherapy-induced toxicities such as oral mucositis, ocular toxicity, onycholysis and peripheral neuropathy \[[@CR11]\]. Of these debilitating side effects, chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity of several neurotoxic chemotherapeutic agents, manifesting as severe pain and tingling sensation in the finger and toe tips \[[@CR30]\]. A recent meta-analysis of more than 4000 chemotherapy-treated patients found the prevalence of CIPN to be 68.1% within the first month of chemotherapy treatment, 60.0% at 3 months and 30.0% at 6 months \[[@CR24]\]. Currently, with no available cure, the treatment is limited to symptomatic pharmacological interventions and dose reduction which in turn reduces the efficacy of the chemotherapy itself.

In a recent trial reported by Hanai et al. ([@CR9]), cryotherapy in the form of frozen gloves was effective in preventing and reducing the occurrence of CIPN \[[@CR9]\]. Similarly, inspired by scalp cooling therapy to combat chemotherapy-induced alopecia (CIA) \[[@CR7], [@CR15]\], several groups have demonstrated promising results that the use of frozen gloves and socks concomitantly with the chemotherapy infusion is efficacious in reducing CIPN \[[@CR4], [@CR9], [@CR23], [@CR29], [@CR31], [@CR32]\]. However, latest reports indicate that the frozen gloves have been recalled due to incidences of frostbite and other patient safety issues \[[@CR10]\]. Moreover, this form of cooling has other major limitations such as lack of stable thermoregulation (ability to change the temperature of the hypothermia delivered according to tolerability) and the need to frequently replace the frozen gloves or ice packs, leading to "breaks" in the hypothermia delivery \[[@CR3]\].

The role of continuous-flow limb cooling in decreasing the incidence of CIPN has been previously described in studies by our group \[[@CR2], [@CR25]\]. Coolant temperature of 22 °C was determined to be the lowest tolerable temperature in healthy volunteers for a duration of 3 h (corresponding to the duration of chemotherapy) \[[@CR2]\]. Using these data, a trial was conducted in cancer patients undergoing adjuvant paclitaxel chemotherapy with concomitant continuous-flow cooling purely on the lower limbs \[[@CR25]\]. To have an early initial signal of efficacy, an internal randomization was performed by administering unilateral lower limb cooling while the other was a paired-control. Only a moderate degree of cooling was achieved, with continuous-flow cooling alone, due to tolerability issues with lower temperatures. However, cancer subjects showed mild improvement in nerve conduction in the cooled leg compared to the control \[[@CR25]\]. After much internal research, it was discovered that the addition of pressure to cooling (cryocompression) allowed for a greater level of tolerability and degree of cooling. Here, the results of our study exploring cryocompression as a means to achieve greater magnitude of regional hypothermia with similar tolerance levels towards efficacious alleviation of CIPN is described. Cryocompression of the limbs was carried out concomitantly during chemotherapy. Tolerability and skin temperature changes were assessed, accompanied by neurophysiological and clinical assessments of neuropathy. The results of the above-mentioned assessments in subjects who underwent cryocompression were also compared with those who underwent continuous-flow cooling during chemotherapy and controls (from our previous study \[[@CR25]\]).

Material and method {#Sec2}
===================

Study design {#Sec3}
------------

The study was conducted at the National University Hospital, Singapore from November 2015 to February 2017 in accordance with the protocol approved by the Institutional Review Board of the National Health Group, Singapore. The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and the 1964 Helsinki declaration and its later amendments. Cancer patients scheduled to receive taxane-based (weekly paclitaxel, 80 mg/m^3^ or 3-weekly docetaxel, 75 mg/m^3^) chemotherapy were invited to participate in the study. All subjects were informed orally and in writing about the aims of the study and written consent for participation was sought and documented.

The inclusion/exclusion criteria were designed as follows. The study population comprised of cancer patients who were eligible for recruitment if they fulfilled the following criteria: (i) aged 21--80 years; (ii) signed informed consent from patient or legal representative; (iii) no history of neuropathy; (iv) Eastern Cooperative Oncology Group (ECOG) performance status 0; and (v) no history of hospitalization in the past 6 months. Patients were ineligible for the study if they had: (i) open skin wounds or ulcers of the limbs; or (ii) history of Raynaud's phenomenon, peripheral vascular disease, or poorly-controlled diabetes (HbA1c \> 10%).

During every cycle of chemotherapy, premedication drugs (dexamethasone, diphenhydramine and ranitidine) were administered 30 min prior to the taxane infusion. The taxane chemotherapy was administered as a 1-h infusion (Fig. [1](#Fig1){ref-type="fig"}). The chemotherapy unit's ambient temperature was adjusted to 21 °C via air-conditioning. Enrolled cancer patients received four-limb cryocompression at 16 °C and cyclic pressure (5--15 mmHg) (these parameters were determined as the lowest tolerable in a healthy subject study) concurrently with their chemotherapy. The study protocol in Fig. [1](#Fig1){ref-type="fig"} indicates the sequence of treatments, comprising of a pre-cooling period (1 h), continued with the taxane infusion and a post-cooling period (on average, 30 min after the end of the taxane infusion). Overall, hypothermia was administered for no longer than 4 h. Safety and tolerability of the cryocompression in cancer patients were assessed during the cryocompression regime as shown in Fig. [1](#Fig1){ref-type="fig"}, through well-defined tolerability measures including three validated scales: visual analogue pain scale (VAS), subjective tolerance scale (STS) and the shivering assessment scale (SAS) \[[@CR25]\]. A detailed safety protocol was followed for coolant thermoregulation, should the patient find the hypothermia intolerable \[[@CR25]\].Fig. 1Trial flow diagram. **a** Schematic of a single chemo-cryocompression session indicating that limb hypothermia was administered as three parts: (i) pre-cooling (60 min) along with administration of pre-medication drugs, followed by (ii) cooling during taxane infusion (60 min) and finally a (iii) post-cooling phase (30 min). The green dots indicate the time points at which tolerability scores were assessed. **b** Overall schematic of the study which constituted up to 12 weeks of chemotherapy. NCS assessments were conducted before the start (NCS~pre~), at the end of chemotherapy (NCS~post~) and after three months (NCS~3m~)

Cryocompression was applied to the subjects via a Game Ready 2.0 Refurbished System (CoolSystems, Inc., CA, USA), which simultaneously applied active cyclical pneumatic compression (cycling from 5--15 mmHg every 5 min) and cooling to the limbs through limb wraps attached to a thermoregulator. The system comprised of a portable thermoregulator control unit together with arm and leg cooling wraps, geometrically designed to comfortably fit around the subject's limbs and could be easily applied and taken off. The control unit circulated the coolant (water) and air through the cooling wraps to cool and compress the wrapped limb. Skin surface temperature was measured using wireless temperature sensors (VitalSense, Philips Respironics, US) placed at evenly spaced locations on all four limbs \[[@CR2], [@CR25]\]. Temperature was continuously monitored throughout the duration of cryocompression and the data recorded through a wireless monitor every minute. Core body temperature (aural) was monitored and recorded once every hour throughout cryocompression.

Assessment of neuropathy {#Sec4}
------------------------

Nerve conduction study (NCS), including evaluation of sensory and motor nerve functions, was conducted at three time points---before the start of chemotherapy (NCS~pre~), after chemotherapy (NCS~post~) and 3 months after chemotherapy (NCS~3m~) (Fig. [1](#Fig1){ref-type="fig"}). Tests were performed as previously standardized by Karandreas et al. (1995) and Ping Ng et al. (2013); sensory nerve action potential (SNAP) amplitudes and sensory nerve conduction velocities were measured in the bilateral sural, superficial peroneal, saphenous, medial and lateral plantar nerves \[[@CR12]\]. Compound motor action potential (cMAP) amplitudes and motor nerve conduction velocities were evaluated in the bilateral common peroneal and tibial nerves \[[@CR22]\]. To allow for homogeneity and comparability of study populations, we only focused on patients who underwent weekly-paclitaxel chemotherapy for our exploratory efficacy analysis.

We also compared the efficacy of cryocompression and continuous-flow cooling by comparing data from this study to our previous study where cancer patients received unilateral leg cooling (without compression) together with their chemotherapy while the study's uncooled limbs were treated as the control group \[[@CR25]\].

Clinical evaluation using the modified total neuropathy score (TNS) was performed at the same time points as the NCS \[[@CR28]\]. Clinician-assessed peripheral sensory neuropathy was recorded once every 3 weeks using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Statistical analysis {#Sec5}
--------------------

The temporal trend of skin temperature changes, over the duration of hypothermia was summarized as a mean of the recorded temperatures for all cycles of hypothermia for all patients. Similarly, tolerability to limb hypothermia was analysed as an average of all patients' tolerance scores across all cycles of hypothermia. Sensory and motor nerve parameters of amplitude and velocity, at every NCS visit, were analysed as relative percentage changes with respect to the first NCS visit (NCS~pre~) and averaged across patients.

Continuous variables are shown as mean ± S.D. (standard deviation). A paired *t* test was used to compare the temperature and NCS values between time points of each individual subject. NCS~3m~ values of subjects who underwent cryocompression were compared with those of control group using Welch's *t* test. A two-tailed *p* value \< 0.05 was considered statistically significant. All statistical analyses were performed in Microsoft Excel (V.12.0 for Windows, Microsoft Corp., Washington, USA).

Results {#Sec6}
=======

Thirteen cancer patients (mean age 55 years, range 33--69 years) scheduled to receive taxane-based chemotherapy participated in the study. The patient characteristics are detailed in Table [1](#Tab1){ref-type="table"}. All patients completed their scheduled cycles of chemotherapy and nerve conduction assessments without early termination or withdrawal. On an average, the patients received a cumulative taxane dose of 856.0 (375.0--960.0) mg/m^2^ of either paclitaxel or docetaxel.Table 1Baseline patient characteristicsVariables*N* (%)\
(total *N* = 13)Mean (range)Age (years)--55 (33--69)Weight (kg)--70 (64--78)Height (cm)--158 (148--168)BSA (m^2^) baseline--1.75 (1.65--1.91)Cumulative dose of taxane (mg/m^2^)--856.0 (375.0--960.0)Cancer type/chemo regimen--Breast/weekly paclitaxel11 (85)Prostate/3-weekly docetaxel2 (15)TNS baseline--07 (54)11 (8)23 (23)32 (15)

Safety and tolerability {#Sec7}
-----------------------

Cryocompression (at 16 °C and dynamic compression) was overall well tolerated as measured by a well-defined range of tolerability measures (Supplementary Figure [S1](#MOESM1){ref-type="media"} a--c). Premature termination of cooling was not necessary for any of the patients. Only one patient (for 1 out of a total 142 cycles) required an intra-cycle thermoregulator temperature increase of 1 °C towards the end of a hypothermia session. Temporary erythema lasting a few minutes was observed upon removal of the cooling wraps. Overall, no serious or lasting adverse events were encountered as a result of limb hypothermia (Supplementary Table [S1](#MOESM1){ref-type="media"}). On average, patients' core body temperature recorded negligible changes of 0.07 ± 0.41 °C averaged across all chemotherapy cycles. In comparison, subjects who underwent continuous-flow cooling displayed mild intolerance to 22 °C (large error bars in Supplementary Figure [S1](#MOESM1){ref-type="media"} f). Continuous-flow cooling temperatures lower than 22 °C was not tolerated by healthy volunteers in our previous study \[[@CR2]\].

Skin temperature changes with limb hypothermia {#Sec8}
----------------------------------------------

Skin temperature changes on the limbs were recorded and averaged across all patients over all 142 cycles. At the end of duration of cryocompression, a mean skin temperature drop of 2.9 ± 2.3 °C and 3.8 ± 1.7 °C was achieved on the arms and legs, respectively. On an average, cryocompression achieved a skin temperature decrease of 2.32 °C lower than continuous-flow cooling (Fig. [2](#Fig2){ref-type="fig"}). Overall, cryocompression demonstrated significantly greater skin temperature reductions compared to both the continuous-flow cooling and the control groups (*p* \< 0.0001)Fig. 2Comparison of skin temperature changes with and without limb hypothermia via cooling and cryocompression techniques. The relative changes in skin surface temperature in the **a**) shin, **b**) calf, **c**) toe and **d**) foot plantar regions over the duration of chemotherapy indicate that cryocompression (blue) offers the best temperature drop compared to continuous-flow cooling (green). The non-cooled limb was considered as control (red) which showed a minor temperature drop as well, owing to the low room temperature. ^\*\*^ indicates *p* \< 0.0001

Clinical neuropathy {#Sec9}
-------------------

The TNS grade of CIPN reported during all the three visits were documented (Supplementary Figure [S2](#MOESM1){ref-type="media"}). Baseline TNS ranged between zero and three for all patients, indicating absence of any baseline neuropathy. Clinician-investigator assessed CTCAE measurement of sensory CIPN was also collected \[[@CR6]\]. None of the patients experienced grade 2 or higher sensory CIPN as the worst-recorded grade. Six (46%) had grade 0, and 7 (54%) had CTCAE grade 1 CIPN (Supplementary Table [S1](#MOESM1){ref-type="media"}).

Nerve conduction changes {#Sec10}
------------------------

NCS analysis was performed for 11 (out of 13) subjects who received paclitaxel chemotherapy (two subjects underwent docetaxel chemotherapy and were included for safety analysis only). Changes at NCS~post~ and NCS~3m~ were calculated as relative changes from baseline (NCS~pre~). NCS analysis following cryocompression showed preservation of cMAP amplitudes at NCS~post~ and NCS~3m~ (NCS~post~ vs. NCS~pre~ and NCS~3m~ vs. NCS~pre~ of the peroneal nerve were not significant; *p* \> 0.05, indicating preservation of NCS parameters) (Fig. [3](#Fig3){ref-type="fig"} (blue), Supplementary Figure [S3](#MOESM1){ref-type="media"} and Table [2](#Tab2){ref-type="table"}). On the other hand, the control group showed significant decrease in cMAPs at NCS~3m~ and NCS~post~ compared to NCS~pre~ (Fig. [3](#Fig3){ref-type="fig"} (red), Supplementary Figure [S3](#MOESM1){ref-type="media"} and Table [2](#Tab2){ref-type="table"}). Moreover, the cMAPs at NCS~3m~ of subjects who underwent cryocompression was significantly higher compared to the controls (NCS~3m~ cryocompression vs. NCS~3m~ control: ankle stimulation: 8.1 ± 21.4%, *p* = 0.004; below fibula head stimulation: 12.7 ± 25.6%, *p* = 0.0008; above fibula head stimulation: 9.4 ± 24.3%, *p* = 0.002) (Fig. [3](#Fig3){ref-type="fig"}, Supplementary Figure [S3](#MOESM1){ref-type="media"} and Table [2](#Tab2){ref-type="table"}). SNAP amplitudes in all subjects continued to significantly deteriorate at NCS~post~ and NCS~3m~ compared to NCS~pre~ in all three groups (i.e., control, cooling and cryocompression). Limb hypothermia did not seem to significantly change outcomes compared to the control group (without hypothermia) (Table [3](#Tab3){ref-type="table"}). Motor and sensory nerve velocities remained largely unaffected at NCS~post~ and NCS~3m~ in all three groups. Further, cryocompression did not affect nerve velocities at NCS~3m~ (Tables [2](#Tab2){ref-type="table"}--[3](#Tab3){ref-type="table"}).Fig. 3Comparison of nerve conduction changes with and without limb hypothermia via cooling and cryocompression techniques. The changes in nerve conduction amplitudes in the motor nerves (**a**--**c**) at three time points---before, end of chemotherapy and after three months indicate that cryocompression (blue) better preserves motor nerve conduction amplitudes compared to continuous-flow cooling (green). The non-cooled limb was considered as control (red), continued to deteriorate. ^\*\*^ indicates *p* \< 0.01 and ^\*\*\*^ indicates *p* \< 0.001Table 2Absolute changes (from baseline NCS, NCS~pre~) in motor nerve conduction amplitude and velocity at the end of chemotherapy (NCS~post~) and after three months (NCS~3m~). Percentage changes are shown in bracketsMotor amplitudeδ (3 months)δ (6 months)Cryocompression\
μV (%)Cooling\
μV (%)Control\
μV (%)Cryocompression\
μV (%)Cooling\
μV (%)Control\
μV (%)EDB (ankle)0.07(− 0.43)− 0.81(− 14.28)− 0.66(− 11.07)0.30(8.14)− 0.43(− 4.79)− 0.83(− 19.48)EDB (below fib head)0.09(0.37)− 0.73(− 14.47)− 0.61(− 12.8)0.37 (12.71)− 0.46(− 5.7)− 0.85(− 21.8)EDB (above fib head)0.08 (0.31)− 0.77(− 16.3)− 0.62(− 12.67)0.25(9.37)− 0.49(− 7.79)− 0.86(− 22.3)AH (ankle)− 1.2(− 9.45)− 1.07(− 8.38)− 1.76(− 12.81)− 1.69(− 8.76)− 1.12(− 10.40)− 1.96(− 14.09)AH (knee)− 0.67(− 3.02)− 0.22(− 2.07)− 0.92(− 7.73)− 1.40(− 12.57)− 0.58(− 6.17)− 1.83(− 16.53)Motor velocityCryocompressionm/s (%)Coolingm/s (%)Controlm/s (%)Cryocompressionm/s (%)Coolingm/s (%)Controlm/s (%)EDB (below fib head)− 1.32(− 2.82)− 1.43(− 2.85)− 0.97(− 1.93)1.81(4.66)0.22(0.9)0.14(0.5)EDB (above fib head)− 0.95(− 0.58)− 3.28(− 5.84)− 0.08(0.67)− 1.54(− 1.31)− 1.99(− 2.43)2.56(6.6)AH (knee)− 0.99(− 1.23)− 2.8(− 5.75)− 1.46(− 2.81)0.13(1.61)− 0.66(− 1.13)− 0.61(− 1.1)Table 3Absolute changes (from baseline NCS, NCS~pre~) in sensory nerve conduction amplitude and velocity at the end of chemotherapy (NCS~post~) and after 3 months (NCS~3m~). Percentage changes are shown in bracketsSensory amplitudeδ (3 months)δ (6 months)Cryocompression\
μV (%)Cooling\
μV (%)Control\
μV (%)Cryocompression\
μV (%)Cooling\
μV (%)Control\
μV (%)Sural− 5.68(− 28.09)− 3.92(− 19.20)− 4.39(− 22.9)− 5.13(− 26.69)− 4.15(− 22.66)− 5.43(− 28.5)Superficial peroneal− 5.34(− 23.29)− 7.61(− 32.14)− 7.68(− 32.9)− 7.87(− 28.15)− 9.5(− 39.21)− 8.78(− 37.57)Saphenous− 1.15(− 21.95)− 1.38(− 20.08)− 1.73(− 29.65)− 1.62(− 27.49)− 1.77(− 27.3)− 1.86(− 27.58)Medial plantar− 4.41(− 34.63)− 6.95(− 54.78)− 7.26(− 55.78)− 5.04(− 44.81)− 7.82(− 58.95)− 7.98(− 59.35)Lateral plantar− 2.97(− 16.83)− 2.02(− 37.82)− 2.35(− 41.88)− 3.28(− 48.14)− 2.36(− 51.57)− 2.54(− 53.91)Sensory velocityCryocompressionm/s (%)Coolingm/s (%)Controlm/s (%)Cryocompressionm/s (%)Coolingm/s (%)Controlm/s (%)Sural− 3.88(− 4.84)1.99(1.89)− 0.69(− 0.66)0.81(3.63)6.26(8.62)3.83(8.61)Superficial peroneal− 4.76(− 5.37)0.12(0.95)− 1.07(− 1.43)− 1.29(0.3)4.5(8.95)4.77(8.59)Saphenous− 2.58(− 2.78)− 0.09(1.86)1.36(5.85)1.92(6.44)5.05(12.02)8.33(21.12)Medial plantar2.15(4.99)− 7.92(− 6.89)− 5.46(− 9.49)− 6.28(− 8.27)− 7.11(− 5.15)− 2.74(− 4.47)Lateral plantar− 3.06(− 3.93)− 2.73(− 4.51)0.09(0.85)− 4.7(− 4.82)− 2.15(− 3.24)0.08(0.51)

Changes in motor amplitudes (over the EDB shown in Fig. [3](#Fig3){ref-type="fig"}) at NCS~3m~ showed a correlation with skin temperature changes (*r* = 0.4).

Discussions {#Sec11}
===========

In this study, we have demonstrated that the addition of pressure to cooling (cryocompression) allows for delivery of significantly lower degrees of hypothermia, resulting in lower skin temperatures. This mode of delivery of regional hypothermia is well tolerated and can be administered over multiple cycles of chemotherapy. Moreover, cryocompression may potentially improve the efficacy of preventing CIPN compared to continuous-flow limb cooling, however, this remains to be demonstrated in further studies.

Studies describe compression contributing to improved tolerability of pain over long durations of hypothermia administered post-surgery by reducing the formation of oedema \[[@CR5]\]. In particular, a study by Murgier and Cassier (2014) showed that dynamic compression together with cooling was more effective in reducing postoperative pain than static compression with cooling \[[@CR19]\]. The gate control theory of pain explains how non-painful sensory inputs could inhibit pain sensations from being transmitted to the brain \[[@CR16]\]. This could explain how compression, especially dynamic compression, works to improve pain management and hypothermia tolerance.

Compression, often used in combination with cryotherapy for care of acute injuries appears to improve tolerability, magnitude and depth of hypothermia. Several studies have repeatedly and meticulously documented that cryocompression results in significantly higher magnitude of surface and even intramuscular temperatures than cryotherapy alone \[[@CR17], [@CR27]\]. The enhanced cooling effect with addition of compression may be attributed to the fact that it improves the contact between tissue and cooling interface and also the insulating effect which the layer of compression adds.

We also observed that the efficacy of cryocompression in preservation of peroneal motor nerve function was better than cryotherapy and control (Fig. [3](#Fig3){ref-type="fig"} and Tables [2](#Tab2){ref-type="table"}--[3](#Tab3){ref-type="table"}). However, sensory nerve function changes were not found to be different across the three groups \[[@CR1], [@CR20], [@CR21]\]. It is important to note, however, that the NCS findings were exploratory in nature and not intended as a primary objective of the study. Moreover, NCS may not be the most reliable method of measuring CIPN \[[@CR18]\]. We postulate that the enhanced cooling is a major factor for the vasoconstriction-driven neuroprotection. However, another notable attribute is that compression itself enhances vasoconstriction. Literature reports that compression greater than 30 to 40 mmHg reduces blood flow \[[@CR17]\]; however, compression alone would not be able to produce the sufficient vasoconstrictive effect as offered by cryocompression.

Another crucial factor influencing the therapeutic efficacy of hypothermia for chemo-induced toxicities is the therapy protocol. Studies of scalp cooling have shown that initiating cooling 30 to 45 min prior to the administration of chemotherapy is crucial for vasoconstriction-induced neuroprotection \[[@CR13]\]. Our temperature data show that the first 60 min is the time period where the maximal cooling occurs after which the tissue attains a thermal stability and hence it is important to attain this state before onset of chemotherapy (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR26]\]. Moreover, our results concur with that reported by Merrick et al., (1993) in that cryocompression attains a lower temperature faster than cryotherapy (cooling without compression) indicating that compression increases the rate of cooling \[[@CR17]\]. Hence, achieving sufficient vasoconstriction before the onset of chemotherapy is a key to enhancing the therapeutic efficacy in alleviating CIPN. As indicated in Fig. [1](#Fig1){ref-type="fig"}, our study initiates hypothermia as a pre-cooling phase before the actual golden period, i.e., during chemotherapy, and followed by a post-cooling phase to lock in the vasoconstrictive effect without causing a rewarming effect.

Several studies have employed frozen gloves as a mode of cryotherapy in preventing CIPN \[[@CR4], [@CR8], [@CR9], [@CR14], [@CR23], [@CR29], [@CR31], [@CR32]\]. These studies have demonstrated frozen gloves are able to deliver considerable regional hypothermia, however, this effect is not sustained or stable thereby potentially reducing the efficacy of vasoconstriction. Due to the need for change of the frozen gloves every 45--60 min, there is a lack of thermal homeostasis. This process is not only cumbersome but also results in occurrences of intolerance and frostbite \[[@CR10]\].

Our study serves as a pilot to demonstrate that cryocompression is a safe and tolerable therapeutic strategy for alleviating CIPN in patients with cancer undergoing taxane treatment. Limitations of the pilot study include a small sample size and the lack of a randomized, prospective control. These findings would need to be validated in a larger prospective study, preferably with randomization. Similar to other supportive care measures such as scalp cooling to reduce CIA, cryocompression may serve to improve the quality of life in cancer patients during and after treatment and also support the delivery of optimal chemotherapy by preventing a dose delay or reduction.
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CIA

:   Chemotherapy-induced alopecia

CIPN

:   Chemotherapy-induced peripheral neuropathy

cMAP

:   Compound muscle action potentials

CTCAE

:   Common terminology criteria for adverse events

ECOG

:   Eastern Cooperative Oncology Group performance status

NCS

:   Nerve Conduction Study

NCS~pre~

:   NCS before chemotherapy

NCS~post~

:   NCS at end of chemotherapy

NCS~3m~

:   NCS at 3 months after chemotherapy

S.D.

:   Standard deviation

SAS

:   Shivering Assessment Scale

SNAP

:   Sensory nerve action potentials

STS

:   Subjective Tolerance Scale

TNS

:   Total Neuropathy Score

VAS

:   Visual Analogue Scale
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